Tirzepatide

What it is

Tirzepatide is a once-weekly subcutaneous injection that activates both GIP and GLP-1 receptors — a dual mechanism unique among approved weight medications.

FDA-approved for chronic weight management (Zepbound) and type 2 diabetes (Mounjaro).

How it works

Dual receptor activation produces greater appetite suppression, slower gastric emptying, and improved insulin sensitivity than single-mechanism GLP-1 medications.

In menopausal weight management, this is often the most effective single tool when combined with resistance training and adequate protein.

Who it's for

• BMI ≥30, or BMI ≥27 with weight-related comorbidity
• Patients who have plateaued on or did not tolerate semaglutide
• Patients committed to lifestyle changes

Who should not take it

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Pregnancy or planned pregnancy
• History of pancreatitis (relative contraindication)

Common side effects

• Nausea — most common, usually transient
• Constipation or diarrhea
• Reduced appetite (the intended effect — but eat enough protein)

Evidence summary

• SURMOUNT-1 trial: mean weight loss of 22.5% at the 15 mg dose at 72 weeks.

FAQ

Sources

• U.S. Food & Drug Administration
• SURMOUNT-1 Trial — NEJM 2022

Symptoms Tirzepatide can help treat

Other medications

This page is educational and is not a substitute for a clinical evaluation. Whether any medication is appropriate for you depends on your full medical history. Kindr providers make individualized prescribing decisions during a clinical visit.